{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:51:29Z","timestamp":1792594289281,"version":"4.5.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07913-3","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:27:25Z","timestamp":1784096845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Apelin-APJ Axis in Heart Failure: Mechanistic Insights, Clinical Evidence, and Translational Challenges"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9541-0801","authenticated-orcid":false,"given":"Dominic Marcel","family":"Alfonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-0062","authenticated-orcid":false,"given":"Jenica Clarisse","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4033-7646","authenticated-orcid":false,"given":"Mary Christie","family":"Palabrica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"10159","key":"7913_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7.","journal-title":"Lancet"},{"key":"7913_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics\u20142021 update: a report from the American Heart Association. Circulation. 2021. https:\/\/doi.org\/10.1161\/CIR.0000000000000950.","journal-title":"Circulation"},{"issue":"5","key":"7913_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jchf.2024.04.001","volume":"12","author":"B Bozkurt","year":"2024","unstructured":"Bozkurt B. Concerning trends of rising heart failure mortality rates. JACC Heart Fail. 2024;12(5):970\u20132. https:\/\/doi.org\/10.1016\/j.jchf.2024.04.001.","journal-title":"JACC Heart Fail"},{"issue":"20","key":"7913_CR4","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. J Am Coll Cardiol. 2017;70(20):2476\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.074.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"7913_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591\u2013602. https:\/\/doi.org\/10.1038\/nrcardio.2017.65.","journal-title":"Nat Rev Cardiol"},{"issue":"20","key":"7913_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262010087","volume":"26","author":"R Wyderka","year":"2025","unstructured":"Wyderka R, Osuch \u0141, O\u0142pi\u0144ska B, \u0141oboz-Rudnicka M, Diakowska D, Le\u015bk\u00f3w A, et al. The impact of the apelinergic system on the cardiovascular system. IJMS. 2025;26(20):10087. https:\/\/doi.org\/10.3390\/ijms262010087.","journal-title":"IJMS"},{"issue":"5","key":"7913_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000033522.37861.69","volume":"91","author":"I Szokodi","year":"2002","unstructured":"Szokodi I, Tavi P, F\u00f6ldes G, Voutilainen-Myllyl\u00e4 S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91(5):434\u201340. https:\/\/doi.org\/10.1161\/01.RES.0000033522.37861.69.","journal-title":"Circ Res"},{"issue":"1","key":"7913_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cardiores.2004.08.018","volume":"65","author":"E Ashley","year":"2005","unstructured":"Ashley E, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65(1):73\u201382. https:\/\/doi.org\/10.1016\/j.cardiores.2004.08.018.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"7913_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10741-015-9475-x","volume":"20","author":"A Folino","year":"2015","unstructured":"Folino A, Montarolo PG, Samaja M, Rastaldo R. Effects of apelin on the cardiovascular system. Heart Fail Rev. 2015;20(4):505\u201318. https:\/\/doi.org\/10.1007\/s10741-015-9475-x.","journal-title":"Heart Fail Rev"},{"issue":"17","key":"7913_CR10","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/cvr\/cvad171","volume":"119","author":"FA Chapman","year":"2023","unstructured":"Chapman FA, Maguire JJ, Newby DE, Davenport AP, Dhaun N. Targeting the apelin system for the treatment of cardiovascular diseases. Cardiovasc Res. 2023;119(17):2683\u201396. https:\/\/doi.org\/10.1093\/cvr\/cvad171.","journal-title":"Cardiovasc Res"},{"issue":"28","key":"7913_CR11","doi-asserted-by":"publisher","first-page":"21061","DOI":"10.1074\/jbc.M908417199","volume":"275","author":"M Hosoya","year":"2000","unstructured":"Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and Functional Characteristics of APJ. J Biol Chem. 2000;275(28):21061\u20137. https:\/\/doi.org\/10.1074\/jbc.M908417199.","journal-title":"J Biol Chem"},{"issue":"1","key":"7913_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1046\/j.1471-4159.2000.0740034.x","volume":"74","author":"DK Lee","year":"2000","unstructured":"Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of Apelin, the Ligand for the APJ Receptor. J Neurochem. 2000;74(1):34\u201341. https:\/\/doi.org\/10.1046\/j.1471-4159.2000.0740034.x.","journal-title":"J Neurochem"},{"issue":"4","key":"7913_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.bbrc.2007.04.017","volume":"357","author":"K Farkasfalvi","year":"2007","unstructured":"Farkasfalvi K, Stagg MA, Coppen SR, Siedlecka U, Lee J, Soppa GK, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun. 2007;357(4):889\u201395. https:\/\/doi.org\/10.1016\/j.bbrc.2007.04.017.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"7913_CR14","doi-asserted-by":"publisher","first-page":"H1904","DOI":"10.1152\/ajpheart.00686.2009","volume":"297","author":"DN Charo","year":"2009","unstructured":"Charo DN, Ho M, Fajardo G, Kawana M, Kundu RK, Sheikh AY, et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol. 2009;297(5):H1904\u201313. https:\/\/doi.org\/10.1152\/ajpheart.00686.2009.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"18","key":"7913_CR15","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/eurheartj\/ehr389","volume":"33","author":"D Pchejetski","year":"2012","unstructured":"Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2012;33(18):2360\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehr389.","journal-title":"Eur Heart J"},{"issue":"5","key":"7913_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cmet.2008.10.003","volume":"8","author":"C Dray","year":"2008","unstructured":"Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Bul\u00e9on M, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008;8(5):437\u201345. https:\/\/doi.org\/10.1016\/j.cmet.2008.10.003.","journal-title":"Cell Metab"},{"issue":"1","key":"7913_CR17","doi-asserted-by":"publisher","DOI":"10.22037\/aaem.v13i1.2414","volume":"13","author":"MM Hasheminezhad","year":"2024","unstructured":"Hasheminezhad MM, Mirzad M, Sepehry Vafa S, Moradi AR, Mahdavi NS, Azizi Y, et al. Early administration of apelin could prevent heart failure following myocardial injury; a systematic review and meta-analysis. Arch Acad Emerg Med. 2024;13(1):e4. https:\/\/doi.org\/10.22037\/aaem.v13i1.2414.","journal-title":"Arch Acad Emerg Med"},{"issue":"6","key":"7913_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.devcel.2013.11.002","volume":"27","author":"SC Chng","year":"2013","unstructured":"Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013;27(6):672\u201380. https:\/\/doi.org\/10.1016\/j.devcel.2013.11.002.","journal-title":"Dev Cell"},{"issue":"6172","key":"7913_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248636","volume":"343","author":"A Pauli","year":"2014","unstructured":"Pauli A, Norris ML, Valen E, Chew GL, Gagnon JA, Zimmerman S, et al. Toddler: an embryonic signal that promotes cell movement via apelin receptors. Science. 2014;343(6172):1248636. https:\/\/doi.org\/10.1126\/science.1248636.","journal-title":"Science"},{"issue":"11","key":"7913_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacc.2008.06.013","volume":"52","author":"AG Japp","year":"2008","unstructured":"Japp AG, Cruden NL, Amer DAB, Li VKY, Goudie EB, Johnston NR, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52(11):908\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2008.06.013.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"7913_CR21","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/CIRCULATIONAHA.109.911339","volume":"121","author":"AG Japp","year":"2010","unstructured":"Japp AG, Cruden NL, Barnes G, Van Gemeren N, Mathews J, Adamson J, et al. Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure. Circulation. 2010;121(16):1818\u201327. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.911339.","journal-title":"Circulation"},{"issue":"3","key":"7913_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/CIRCHEARTFAILURE.111.000077","volume":"6","author":"GD Barnes","year":"2013","unstructured":"Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, et al. Sustained cardiovascular actions of APJ agonism during renin\u2013angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013;6(3):482\u201391. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.000077.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"7913_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacbts.2018.01.013","volume":"3","author":"L Brash","year":"2018","unstructured":"Brash L, Barnes GD, Brewis MJ, Church AC, Gibbs SJ, Howard LSGE, et al. Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension. JACC Basic Transl Sci. 2018;3(2):176\u201386. https:\/\/doi.org\/10.1016\/j.jacbts.2018.01.013.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"7913_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007351","volume":"14","author":"P Gargalovic","year":"2021","unstructured":"Gargalovic P, Wong P, Onorato J, Finlay H, Wang T, Yan M, et al. In vitro and in vivo evaluation of a small-molecule APJ (apelin receptor) agonist, BMS-986224, as a potential treatment for heart failure. Circ Heart Fail. 2021;14(3):e007351. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007351.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"7913_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10557-022-07328-w","volume":"37","author":"P Winkle","year":"2023","unstructured":"Winkle P, Goldsmith S, Koren MJ, Lepage S, Hellawell J, Trivedi A, et al. A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. Cardiovasc Drugs Ther. 2023;37(4):743\u201355. https:\/\/doi.org\/10.1007\/s10557-022-07328-w.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7913_CR26","unstructured":"Bristol-Myers Squibb A, Randomized D-B. Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986224 in Healthy Subjects and Chronic Heart Failure Patients With Reduced Ejection Fraction [Clinical trial registration] [Internet]. clinicaltrials.gov; 2021 Feb [cited 2025 Nov 13]. Clinical trial registration no.: NCT03281122. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03281122"},{"issue":"2","key":"7913_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","volume":"251","author":"K Tatemoto","year":"1998","unstructured":"Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor. Biochem Biophys Res Commun. 1998;251(2):471\u20136. https:\/\/doi.org\/10.1006\/bbrc.1998.9489.","journal-title":"Biochem Biophys Res Commun"},{"key":"7913_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115268","volume":"166","author":"S Gao","year":"2023","unstructured":"Gao S, Chen H. Therapeutic potential of apelin and Elabela in cardiovascular disease. Biomed Pharmacother. 2023;166:115268. https:\/\/doi.org\/10.1016\/j.biopha.2023.115268.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7913_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0167-4889(99)00114-7","volume":"1452","author":"Y Habata","year":"1999","unstructured":"Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1999;1452(1):25\u201335. https:\/\/doi.org\/10.1016\/S0167-4889(99)00114-7.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"3","key":"7913_CR30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.109.134619","volume":"54","author":"JJ Maguire","year":"2009","unstructured":"Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1 ]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease. Hypertension. 2009;54(3):598\u2013604. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.134619.","journal-title":"Hypertension"},{"issue":"1","key":"7913_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ab.2013.07.006","volume":"442","author":"EY Zhen","year":"2013","unstructured":"Zhen EY, Higgs RE, Gutierrez JA. Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Anal Biochem. 2013;442(1):1\u20139. https:\/\/doi.org\/10.1016\/j.ab.2013.07.006.","journal-title":"Anal Biochem"},{"issue":"5","key":"7913_CR32","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1046\/j.1471-4159.2003.01587.x","volume":"84","author":"AD Medhurst","year":"2003","unstructured":"Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84(5):1162\u201372. https:\/\/doi.org\/10.1046\/j.1471-4159.2003.01587.x.","journal-title":"J Neurochem"},{"issue":"16","key":"7913_CR33","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/cbic.201600244","volume":"17","author":"SMK McKinnie","year":"2016","unstructured":"McKinnie SMK, Fischer C, Tran KMH, Wang W, Mosquera F, Oudit GY, et al. The metalloprotease neprilysin degrades and inactivates apelin peptides. ChemBioChem. 2016;17(16):1495\u20138. https:\/\/doi.org\/10.1002\/cbic.201600244.","journal-title":"ChemBioChem"},{"issue":"17","key":"7913_CR34","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","volume":"277","author":"C Vickers","year":"2002","unstructured":"Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838\u201343. https:\/\/doi.org\/10.1074\/jbc.M200581200.","journal-title":"J Biol Chem"},{"issue":"3","key":"7913_CR35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0006-291X(03)01424-4","volume":"308","author":"G F\u00f6ldes","year":"2003","unstructured":"F\u00f6ldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun. 2003;308(3):480\u20135. https:\/\/doi.org\/10.1016\/S0006-291X(03)01424-4.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"7913_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pharmthera.2005.04.001","volume":"107","author":"MJ Kleinz","year":"2005","unstructured":"Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005;107(2):198\u2013211. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.04.001.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"7913_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejheart.2005.10.007","volume":"8","author":"KS Chong","year":"2006","unstructured":"Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8(4):355\u201360. https:\/\/doi.org\/10.1016\/j.ejheart.2005.10.007.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"7913_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.21037\/atm.2020.02.07","volume":"8","author":"W Liu","year":"2020","unstructured":"Liu W, Yan J, Pan W, Tang M. Apelin\/Elabela-APJ: a novel therapeutic target in the cardiovascular system. Ann Transl Med. 2020;8(5):243\u2013243. https:\/\/doi.org\/10.21037\/atm.2020.02.07.","journal-title":"Ann Transl Med"},{"issue":"2","key":"7913_CR39","doi-asserted-by":"publisher","first-page":"H348","DOI":"10.1152\/ajpheart.00693.2017","volume":"315","author":"VN Parikh","year":"2018","unstructured":"Parikh VN, Liu J, Shang C, Woods C, Chang AC, Zhao M, et al. Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition. Am J Physiol Heart Circ Physiol. 2018;315(2):H348-56. https:\/\/doi.org\/10.1152\/ajpheart.00693.2017.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"7913_CR40","doi-asserted-by":"publisher","first-page":"e000249","DOI":"10.1161\/JAHA.113.000249","volume":"2","author":"W Wang","year":"2013","unstructured":"Wang W, McKinnie SMK, Patel VB, Haddad G, Wang Z, Zhabyeyev P, et al. Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia-reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues. JAHA. 2013;2(4):e000249. https:\/\/doi.org\/10.1161\/JAHA.113.000249.","journal-title":"JAHA"},{"issue":"7","key":"7913_CR41","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1021\/acs.jmedchem.5b01549","volume":"59","author":"A Murza","year":"2016","unstructured":"Murza A, Sainsily X, Coquerel D, C\u00f4t\u00e9 J, Marx P, Besserer-Offroy \u00c9, et al. Discovery and structure\u2013activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J Med Chem. 2016;59(7):2962\u201372. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01549.","journal-title":"J Med Chem"},{"issue":"4","key":"7913_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.stem.2015.08.010","volume":"17","author":"L Ho","year":"2015","unstructured":"Ho L, Tan SYX, Wee S, Wu Y, Tan SJC, Ramakrishna NB, et al. ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K\/AKT pathway. Cell Stem Cell. 2015;17(4):435\u201347. https:\/\/doi.org\/10.1016\/j.stem.2015.08.010.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"7913_CR43","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tips.2015.06.002","volume":"36","author":"P Yang","year":"2015","unstructured":"Yang P, Maguire JJ, Davenport AP. Apelin, elabela\/toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36(9):560\u20137. https:\/\/doi.org\/10.1016\/j.tips.2015.06.002.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"7913_CR44","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.celrep.2017.08.014","volume":"20","author":"L Freyer","year":"2017","unstructured":"Freyer L, Hsu CW, Nowotschin S, Pauli A, Ishida J, Kuba K, et al. Loss of Apela Peptide in Mice Causes Low Penetrance Embryonic Lethality and Defects in Early Mesodermal Derivatives. Cell Rep. 2017;20(9):2116\u201330. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.014.","journal-title":"Cell Rep"},{"issue":"6","key":"7913_CR45","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.devcel.2017.08.008","volume":"42","author":"B Sharma","year":"2017","unstructured":"Sharma B, Ho L, Ford GH, Chen HI, Goldstone AB, Woo YJ, et al. Alternative Progenitor Cells Compensate to Rebuild the Coronary Vasculature in Elabela- and Apj-Deficient Hearts. Dev Cell. 2017;42(6):655\u2013e6663. https:\/\/doi.org\/10.1016\/j.devcel.2017.08.008.","journal-title":"Dev Cell"},{"issue":"4","key":"7913_CR46","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1124\/pr.119.017533","volume":"71","author":"C Read","year":"2019","unstructured":"Read C, Nyimanu D, Williams TL, Huggins DJ, Sulentic P, Macrae RGC, et al. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela\/Toddler Is a Second Endogenous Peptide Ligand. Pharmacol Rev. 2019;71(4):467\u2013502. https:\/\/doi.org\/10.1124\/pr.119.017533.","journal-title":"Pharmacol Rev"},{"issue":"6352","key":"7913_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.aam6607","volume":"357","author":"L Ho","year":"2017","unstructured":"Ho L, Van Dijk M, Chye STJ, Messerschmidt DM, Chng SC, Ong S, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science. 2017;357(6352):707\u201313. https:\/\/doi.org\/10.1126\/science.aam6607.","journal-title":"Science"},{"key":"7913_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.107.158659","author":"K Kuba","year":"2007","unstructured":"Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, et al. Impaired heart contractility in apelin gene\u2013deficient mice associated with aging and pressure overload. Circ Res. 2007. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.158659.","journal-title":"Circ Res"},{"issue":"12","key":"7913_CR49","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1161\/CIRCULATIONAHA.116.023218","volume":"135","author":"P Yang","year":"2017","unstructured":"Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, et al. Elabela\/Toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation. 2017;135(12):1160\u201373. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023218.","journal-title":"Circulation"},{"issue":"6","key":"7913_CR50","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.str.2017.04.008","volume":"25","author":"Y Ma","year":"2017","unstructured":"Ma Y, Yue Y, Ma Y, Zhang Q, Zhou Q, Song Y, et al. Structural Basis for Apelin Control of the Human Apelin Receptor. Structure. 2017;25(6):858\u2013e8664. https:\/\/doi.org\/10.1016\/j.str.2017.04.008.","journal-title":"Structure"},{"issue":"30","key":"7913_CR51","doi-asserted-by":"publisher","first-page":"18261","DOI":"10.1074\/jbc.M115.648238","volume":"290","author":"C Deng","year":"2015","unstructured":"Deng C, Chen H, Yang N, Feng Y, Hsueh AJW. Apela Regulates Fluid Homeostasis by Binding to the APJ Receptor to Activate Gi Signaling. J Biol Chem. 2015;290(30):18261\u20138. https:\/\/doi.org\/10.1074\/jbc.M115.648238.","journal-title":"J Biol Chem"},{"issue":"7","key":"7913_CR52","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/cvr\/cvx061","volume":"113","author":"T Sato","year":"2017","unstructured":"Sato T, Sato C, Kadowaki A, Watanabe H, Ho L, Ishida J, et al. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage. Cardiovascular Res. 2017;113(7):760\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvx061.","journal-title":"Cardiovascular Res"},{"key":"7913_CR53","doi-asserted-by":"publisher","first-page":"177302","DOI":"10.1016\/j.ejphar.2025.177302","volume":"991","author":"GTM Wagenaar","year":"2025","unstructured":"Wagenaar GTM, Moll GN. Advances in the therapeutic potentials of ligands of the apelin receptor APJ. Eur J Pharmacol. 2025;991:177302. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177302.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20132","key":"7913_CR54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0378-1119(93)90495-O","volume":"136","author":"BF O\u2019Dowd","year":"1993","unstructured":"O\u2019Dowd BF, Heiber M, Chan A, Heng HHQ, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136(1\u20132):355\u201360. https:\/\/doi.org\/10.1016\/0378-1119(93)90495-O.","journal-title":"Gene"},{"issue":"2","key":"7913_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0925-4773(96)00585-0","volume":"59","author":"E Devic","year":"1996","unstructured":"Devic E, Paquereau L, Vernier P, Knibiehler B, Audigier Y. Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech Dev. 1996;59(2):129\u201340. https:\/\/doi.org\/10.1016\/0925-4773(96)00585-0.","journal-title":"Mech Dev"},{"issue":"1","key":"7913_CR56","doi-asserted-by":"publisher","first-page":"H88","DOI":"10.1152\/ajpheart.00935.2007","volume":"294","author":"AY Sheikh","year":"2008","unstructured":"Sheikh AY, Chun HJ, Glassford AJ, Kundu RK, Kutschka I, Ardigo D, et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol. 2008;294(1):H88\u201398. https:\/\/doi.org\/10.1152\/ajpheart.00935.2007.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"7913_CR57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.regpep.2004.10.019","volume":"126","author":"MJ Kleinz","year":"2005","unstructured":"Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126(3):233\u201340. https:\/\/doi.org\/10.1016\/j.regpep.2004.10.019.","journal-title":"Regul Pept"},{"key":"7913_CR58","doi-asserted-by":"publisher","DOI":"10.2478\/s11658-006-0058-7","author":"P Atluri","year":"2007","unstructured":"Atluri P, Morine K, Liao G, Panlilio C, Berry M, Hsu V, et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett. 2007. https:\/\/doi.org\/10.2478\/s11658-006-0058-7.","journal-title":"Cell Mol Biol Lett"},{"issue":"4","key":"7913_CR59","doi-asserted-by":"publisher","first-page":"H1471","DOI":"10.1152\/ajpheart.00097.2011","volume":"301","author":"J Tao","year":"2011","unstructured":"Tao J, Zhu W, Li Y, Xin P, Li J, Liu M, et al. Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol. 2011;301(4):H1471\u201386. https:\/\/doi.org\/10.1152\/ajpheart.00097.2011.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"7913_CR60","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00395-007-0671-2","volume":"102","author":"JC Simpkin","year":"2007","unstructured":"Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CCT. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injury. Basic Res Cardiol. 2007;102(6):518\u201328. https:\/\/doi.org\/10.1007\/s00395-007-0671-2.","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"7913_CR61","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1139\/bcb-2014-0072","volume":"92","author":"NA Chapman","year":"2014","unstructured":"Chapman NA, Dupr\u00e9 DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochem Cell Biol. 2014;92(6):431\u201340. https:\/\/doi.org\/10.1139\/bcb-2014-0072.","journal-title":"Biochem Cell Biol"},{"issue":"15","key":"7913_CR62","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1096\/fj.04-1930fje","volume":"18","author":"B Masri","year":"2004","unstructured":"Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J. 2004;18(15):1909\u201311. https:\/\/doi.org\/10.1096\/fj.04-1930fje.","journal-title":"FASEB J"},{"key":"7913_CR63","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000138382.57325.5c","author":"MF Berry","year":"2004","unstructured":"Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation. 2004. https:\/\/doi.org\/10.1161\/01.CIR.0000138382.57325.5c.","journal-title":"Circulation"},{"issue":"1","key":"7913_CR64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00395-015-0521-6","volume":"111","author":"\u00c1 Perj\u00e9s","year":"2016","unstructured":"Perj\u00e9s \u00c1, Kilpi\u00f6 T, Ulvila J, Magga J, Alakoski T, Szab\u00f3 Z, et al. Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res Cardiol. 2016;111(1):2. https:\/\/doi.org\/10.1007\/s00395-015-0521-6.","journal-title":"Basic Res Cardiol"},{"issue":"7411","key":"7913_CR65","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature11263","volume":"488","author":"MC Scimia","year":"2012","unstructured":"Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature. 2012;488(7411):394\u20138. https:\/\/doi.org\/10.1038\/nature11263.","journal-title":"Nature"},{"issue":"25","key":"7913_CR66","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJM199812173392503","volume":"339","author":"JN Cohn","year":"1998","unstructured":"Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998;339(25):1810\u20136. https:\/\/doi.org\/10.1056\/NEJM199812173392503.","journal-title":"N Engl J Med"},{"issue":"21","key":"7913_CR67","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"M Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325(21):1468\u201375. https:\/\/doi.org\/10.1056\/NEJM199111213252103.","journal-title":"N Engl J Med"},{"key":"7913_CR68","doi-asserted-by":"publisher","unstructured":"Perj\u00e9s \u00c1, Skoumal R, Tenhunen O, K\u00f3nyi A, Simon M, Horv\u00e1th IG et al. Apelin Increases Cardiac Contractility via Protein Kinase C\u03b5- and Extracellular Signal-Regulated Kinase-Dependent Mechanisms. Bader M, editor. PLoS ONE. 2014;9(4):e93473. https:\/\/doi.org\/10.1371\/journal.pone.0093473","DOI":"10.1371\/journal.pone.0093473"},{"issue":"1","key":"7913_CR69","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1006\/bbrc.2001.6230","volume":"290","author":"B Masri","year":"2002","unstructured":"Masri B, Lahlou H, Mazarguil H, Knibiehler B, Audigier Y. Apelin (65\u201377) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. Biochem Biophys Res Commun. 2002;290(1):539\u201345. https:\/\/doi.org\/10.1006\/bbrc.2001.6230.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"7913_CR70","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.CIR.0000127126.73759.23","volume":"109","author":"DJ Lips","year":"2004","unstructured":"Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109(16):1938\u201341. https:\/\/doi.org\/10.1161\/01.CIR.0000127126.73759.23.","journal-title":"Circulation"},{"issue":"4","key":"7913_CR71","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","volume":"90","author":"BA Rose","year":"2010","unstructured":"Rose BA, Force T, Wang Y. Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale. Physiol Rev. 2010;90(4):1507\u201346. https:\/\/doi.org\/10.1152\/physrev.00054.2009.","journal-title":"Physiol Rev"},{"issue":"5","key":"7913_CR72","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3892\/mmr.2014.1984","volume":"9","author":"X Yang","year":"2014","unstructured":"Yang X, Zhu W, Zhang P, Chen K, Zhao L, Li J, et al. Apelin-13 stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in myocardial microvascular endothelial cells. Mol Med Rep. 2014;9(5):1590\u20136. https:\/\/doi.org\/10.3892\/mmr.2014.1984.","journal-title":"Mol Med Rep"},{"key":"7913_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.632886","volume":"12","author":"G Hu","year":"2021","unstructured":"Hu G, Wang Z, Zhang R, Sun W, Chen X. The role of apelin\/apelin receptor in energy metabolism and water homeostasis: a comprehensive narrative review. Front Physiol. 2021;12:632886. https:\/\/doi.org\/10.3389\/fphys.2021.632886.","journal-title":"Front Physiol"},{"issue":"1","key":"7913_CR74","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1152\/ajpendo.00385.2009","volume":"298","author":"P Yue","year":"2010","unstructured":"Yue P, Jin H, Aillaud M, Deng AC, Azuma J, Asagami T, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiology-Endocrinology Metabolism. 2010;298(1):E59\u201367. https:\/\/doi.org\/10.1152\/ajpendo.00385.2009.","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"issue":"2","key":"7913_CR75","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2337\/db11-0100","volume":"61","author":"C Attan\u00e9","year":"2012","unstructured":"Attan\u00e9 C, Foussal C, Le Gonidec S, Benani A, Daviaud D, Wanecq E, et al. Apelin Treatment Increases Complete Fatty Acid Oxidation, Mitochondrial Oxidative Capacity, and Biogenesis in Muscle of Insulin-Resistant Mice. Diabetes. 2012;61(2):310\u201320. https:\/\/doi.org\/10.2337\/db11-0100.","journal-title":"Diabetes"},{"key":"7913_CR76","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","volume":"5","author":"QG Karwi","year":"2018","unstructured":"Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of Metabolic Flexibility in the Failing Heart. Front Cardiovasc Med. 2018;5:68. https:\/\/doi.org\/10.3389\/fcvm.2018.00068.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"7913_CR77","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circul Res. 2021;128(10):1487\u2013513. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318241.","journal-title":"Circul Res"},{"issue":"6","key":"7913_CR78","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/01.RES.0000261924.76669.36","volume":"100","author":"Y Matsui","year":"2007","unstructured":"Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, et al. Distinct Roles of Autophagy in the Heart During Ischemia and Reperfusion: Roles of AMP-Activated Protein Kinase and Beclin 1 in Mediating Autophagy. Circul Res. 2007;100(6):914\u201322. https:\/\/doi.org\/10.1161\/01.RES.0000261924.76669.36.","journal-title":"Circul Res"},{"issue":"4","key":"7913_CR79","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.yjmcc.2010.12.004","volume":"51","author":"M Kim","year":"2011","unstructured":"Kim M, Tian R. Targeting AMPK for cardiac protection: opportunities and challenges. J Mol Cell Cardiol. 2011;51(4):548\u201353. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.12.004.","journal-title":"J Mol Cell Cardiol"},{"key":"7913_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.630548","volume":"12","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Yan M, Wang C, Wang Q, Chen X, Zhang R, et al. The effects of apelin and elabela ligands on apelin receptor distinct signaling profiles. Front Pharmacol. 2021;12:630548. https:\/\/doi.org\/10.3389\/fphar.2021.630548.","journal-title":"Front Pharmacol"},{"key":"7913_CR81","doi-asserted-by":"publisher","unstructured":"Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008:JCI34871. https:\/\/doi.org\/10.1172\/JCI34871.","DOI":"10.1172\/JCI34871"},{"key":"7913_CR82","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pharmthera.2018.05.013","volume":"190","author":"A Mughal","year":"2018","unstructured":"Mughal A, O\u2019Rourke ST. Vascular effects of apelin: Mechanisms and therapeutic potential. Pharmacol Ther. 2018;190:139\u201347. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.013.","journal-title":"Pharmacol Ther"},{"issue":"6736","key":"7913_CR83","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/21218","volume":"399","author":"D Fulton","year":"1999","unstructured":"Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399(6736):597\u2013601. https:\/\/doi.org\/10.1038\/21218.","journal-title":"Nature"},{"issue":"7327","key":"7913_CR84","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/nature09599","volume":"468","author":"CA Chen","year":"2010","unstructured":"Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MAH, et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature. 2010;468(7327):1115\u20138. https:\/\/doi.org\/10.1038\/nature09599.","journal-title":"Nature"},{"issue":"3","key":"7913_CR85","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0014-5793(98)01705-0","volume":"443","author":"ZP Chen","year":"1999","unstructured":"Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999;443(3):285\u20139. https:\/\/doi.org\/10.1016\/S0014-5793(98)01705-0.","journal-title":"FEBS Lett"},{"issue":"1","key":"7913_CR86","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12551-023-01044-x","volume":"15","author":"S Murali","year":"2023","unstructured":"Murali S, Aradhyam GK. Structure\u2013function relationship and physiological role of apelin and its G protein coupled receptor. Biophys Rev. 2023;15(1):127\u201343. https:\/\/doi.org\/10.1007\/s12551-023-01044-x.","journal-title":"Biophys Rev"},{"key":"7913_CR87","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.avsg.2022.04.033","volume":"84","author":"S Sahinturk","year":"2022","unstructured":"Sahinturk S, Demirel S, Ozyener F, Isbil N. Vascular Functional Effect Mechanisms of Elabela in Rat Thoracic Aorta. Ann Vasc Surg. 2022;84:381\u201397. https:\/\/doi.org\/10.1016\/j.avsg.2022.04.033.","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"7913_CR88","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/cvr\/cvq052","volume":"87","author":"Y Kojima","year":"2010","unstructured":"Kojima Y, Kundu RK, Cox CM, Leeper NJ, Anderson JA, Chun HJ, et al. Upregulation of the apelin\u2013APJ pathway promotes neointima formation in the carotid ligation model in mouse. Cardiovasc Res. 2010;87(1):156\u201365. https:\/\/doi.org\/10.1093\/cvr\/cvq052.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"7913_CR89","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1172\/JCI69608","volume":"123","author":"T Sato","year":"2013","unstructured":"Sato T, Suzuki T, Watanabe H, Kadowaki A, Fukamizu A, Liu PP, et al. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest. 2013;123(12):5203\u201311. https:\/\/doi.org\/10.1172\/JCI69608.","journal-title":"J Clin Invest"},{"issue":"2","key":"7913_CR90","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/ijms20020239","volume":"20","author":"T Sato","year":"2019","unstructured":"Sato T, Kadowaki A, Suzuki T, Ito H, Watanabe H, Imai Y, et al. Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling. IJMS. 2019;20(2):239. https:\/\/doi.org\/10.3390\/ijms20020239.","journal-title":"IJMS"},{"issue":"12","key":"7913_CR91","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1161\/01.CIR.0000091235.94914.75","volume":"108","author":"MM Chen","year":"2003","unstructured":"Chen MM, Ashley EA, Deng DXF, Tsalenko A, Deng A, Tabibiazar R, et al. Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction. Circulation. 2003;108(12):1432\u20139. https:\/\/doi.org\/10.1161\/01.CIR.0000091235.94914.75.","journal-title":"Circulation"},{"issue":"7","key":"7913_CR92","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/j.1476-5381.2010.00821.x","volume":"160","author":"SL Pitkin","year":"2010","unstructured":"Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin\/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol. 2010;160(7):1785\u201395. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00821.x.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"7913_CR93","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1161\/CIRCRESAHA.124.324608","volume":"135","author":"L Tang","year":"2024","unstructured":"Tang L, Qiu H, Xu B, Su Y, Nyarige V, Li P, et al. Microparticle Mediated Delivery of Apelin Improves Heart Function in Post Myocardial Infarction Mice. Circul Res. 2024;135(7):777\u201398. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.324608.","journal-title":"Circul Res"},{"issue":"1","key":"7913_CR94","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcdd9010023","volume":"9","author":"AA Berezin","year":"2022","unstructured":"Berezin AA, Fushtey IM, Berezin AE. Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients. JCDD. 2022;9(1):23. https:\/\/doi.org\/10.3390\/jcdd9010023.","journal-title":"JCDD"},{"issue":"5","key":"7913_CR95","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000533277","volume":"108","author":"T Zhang","year":"2023","unstructured":"Zhang T, Wang X, Wang Z, Zhai J, He L, Wang Y, et al. Canagliflozin Ameliorates Ventricular Remodeling through Apelin\/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats. Pharmacology. 2023;108(5):478\u201391. https:\/\/doi.org\/10.1159\/000533277.","journal-title":"Pharmacology"},{"issue":"24","key":"7913_CR96","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1136\/heartjnl-2023-322742","volume":"109","author":"LR Celant","year":"2023","unstructured":"Celant LR, Wessels JN, Kianzad A, Marcus JT, Meijboom LJ, Bogaard HJ, et al. Restoration of right ventricular function in the treatment of pulmonary arterial hypertension. Heart. 2023;109(24):1844\u201350. https:\/\/doi.org\/10.1136\/heartjnl-2023-322742.","journal-title":"Heart"},{"issue":"1\u20133","key":"7913_CR97","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.regpep.2005.09.032","volume":"133","author":"JP Goetze","year":"2006","unstructured":"Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, et al. Apelin: A new plasma marker of cardiopulmonary disease. Regul Pept. 2006;133(1\u20133):134\u20138. https:\/\/doi.org\/10.1016\/j.regpep.2005.09.032.","journal-title":"Regul Pept"},{"issue":"3","key":"7913_CR98","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4103\/2045-8932.87299","volume":"1","author":"CU Andersen","year":"2011","unstructured":"Andersen CU, Hilberg O, Mellemkj\u00e6r S, Nielsen-Kudsk JE, Simonsen U. Apelin and pulmonary hypertension. Pulm Circ. 2011;1(3):334\u201346. https:\/\/doi.org\/10.4103\/2045-8932.87299.","journal-title":"Pulm Circ"},{"key":"7913_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.904892","volume":"9","author":"C Yang","year":"2022","unstructured":"Yang C, Zhang C, Jia R, Qiao S, Yuan J, Jin Z. Significance and determinants of plasma apelin in patients with obstructive hypertrophic cardiomyopathy. Front Cardiovasc Med. 2022;9:904892. https:\/\/doi.org\/10.3389\/fcvm.2022.904892.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"7913_CR100","doi-asserted-by":"publisher","first-page":"H605","DOI":"10.1152\/ajpheart.00366.2012","volume":"303","author":"L Li","year":"2012","unstructured":"Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2012;303(5):H605\u201318. https:\/\/doi.org\/10.1152\/ajpheart.00366.2012.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"7913_CR101","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/bip.22498","volume":"102","author":"A Murza","year":"2014","unstructured":"Murza A, Belleville K, Longpr\u00e9 J, Sarret P, Marsault \u00c9. Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid. Biopolymers. 2014;102(4):297\u2013303. https:\/\/doi.org\/10.1002\/bip.22498.","journal-title":"Biopolymers"},{"issue":"6","key":"7913_CR102","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.cell.2024.02.004","volume":"187","author":"WW Wang","year":"2024","unstructured":"Wang WW, Ji SY, Zhang W, Zhang J, Cai C, Hu R, et al. Structure-based design of non-hypertrophic apelin receptor modulator. Cell. 2024;187(6):1460\u2013e147520. https:\/\/doi.org\/10.1016\/j.cell.2024.02.004.","journal-title":"Cell"},{"issue":"8","key":"7913_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132898","volume":"5","author":"B Ason","year":"2020","unstructured":"Ason B, Chen Y, Guo Q, Hoagland KM, Chui RW, Fielden M, et al. Cardiovascular response to small-molecule APJ activation. JCI Insight. 2020;5(8):e132898. https:\/\/doi.org\/10.1172\/jci.insight.132898.","journal-title":"JCI Insight"},{"issue":"Supplement1","key":"7913_CR104","doi-asserted-by":"publisher","first-page":"866","DOI":"10.2337\/db25-866-P","volume":"74","author":"S Yan","year":"2025","unstructured":"Yan S, Portillo C, Wang Y, Banicki M, Cochran M, Banicki A, et al. 866-P: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction. Diabetes. 2025;74(Supplement1):866\u2013P. https:\/\/doi.org\/10.2337\/db25-866-P.","journal-title":"Diabetes"},{"issue":"21","key":"7913_CR105","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/jama.2019.6717","volume":"321","author":"SJ Shah","year":"2019","unstructured":"Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, et al. Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019;321(21):2101. https:\/\/doi.org\/10.1001\/jama.2019.6717.","journal-title":"JAMA"},{"issue":"11","key":"7913_CR106","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/ejhf.1591","volume":"21","author":"AA Voors","year":"2019","unstructured":"Voors AA, Bax JJ, Hernandez AF, Wirtz AB, Pap AF, Ferreira AC, et al. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo\u2010controlled trial. Eur J Heart Fail. 2019;21(11):1426\u201333. https:\/\/doi.org\/10.1002\/ejhf.1591.","journal-title":"Eur J Heart Fail"},{"key":"7913_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01281","volume":"9","author":"CMJ Tan","year":"2018","unstructured":"Tan CMJ, Green P, Tapoulal N, Lewandowski AJ, Leeson P, Herring N. The role of neuropeptide Y in cardiovascular health and disease. Front Physiol. 2018;9:1281. https:\/\/doi.org\/10.3389\/fphys.2018.01281.","journal-title":"Front Physiol"},{"issue":"3","key":"7913_CR108","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamacardio.2019.4717","volume":"5","author":"OA Ajijola","year":"2020","unstructured":"Ajijola OA, Chatterjee NA, Gonzales MJ, Gornbein J, Liu K, Li D, et al. Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. JAMA Cardiol. 2020;5(3):318. https:\/\/doi.org\/10.1001\/jamacardio.2019.4717.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"7913_CR109","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11886-022-01668-7","volume":"24","author":"SB Bremner","year":"2022","unstructured":"Bremner SB, Gaffney KS, Sniadecki NJ, Mack DL. A change of heart: human cardiac tissue engineering as a platform for drug development. Curr Cardiol Rep. 2022;24(5):473\u201386. https:\/\/doi.org\/10.1007\/s11886-022-01668-7.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"7913_CR110","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40268-022-00386-3","volume":"22","author":"A Trivedi","year":"2022","unstructured":"Trivedi A, Mather O, Vega S, Hutton S, Hellawell J, Lee E. A phase I, open-label, single-dose study to evaluate the pharmacokinetics, safety, and tolerability of AMG 986 in healthy Japanese subjects. Drugs R D. 2022;22(2):141\u20136. https:\/\/doi.org\/10.1007\/s40268-022-00386-3.","journal-title":"Drugs R D"},{"issue":"6","key":"7913_CR111","doi-asserted-by":"publisher","first-page":"e129433","DOI":"10.1172\/JCI129433","volume":"131","author":"AL Frump","year":"2021","unstructured":"Frump AL, Albrecht M, Yakubov B, Breuils-Bonnet S, Nadeau V, Tremblay E, et al. 17\u03b2-estradiol and estrogen receptor \u03b1 protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. J Clin Invest. 2021;131(6):e129433. https:\/\/doi.org\/10.1172\/JCI129433.","journal-title":"J Clin Invest"},{"issue":"1","key":"7913_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61480-x","volume":"14","author":"C Liu","year":"2024","unstructured":"Liu C, Xiong J, Yi X, Song S, Yang H, Tan W, et al. Decreased plasma ELABELA level as a novel screening indicator for heart failure: a cohort and observational study. Sci Rep. 2024;14(1):11333. https:\/\/doi.org\/10.1038\/s41598-024-61480-x.","journal-title":"Sci Rep"},{"key":"7913_CR113","doi-asserted-by":"publisher","first-page":"638468","DOI":"10.3389\/fcvm.2021.638468","volume":"8","author":"Z Ma","year":"2021","unstructured":"Ma Z, Zhao L, Martin S, Zhang Y, Dong Y, Zhong JC, et al. Lower Plasma Elabela Levels in Hypertensive Patients With Heart Failure Predict the Occurrence of Major Adverse Cardiac Events: A Preliminary Study. Front Cardiovasc Med. 2021;8:638468. https:\/\/doi.org\/10.3389\/fcvm.2021.638468.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"7913_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11835-z","volume":"12","author":"P Janssens","year":"2022","unstructured":"Janssens P, De Loor H, Decuypere JP, Vennekens R, Llorens-Cortes C, Mekahli D, et al. On methods for the measurement of the apelin receptor ligand apelin. Sci Rep. 2022;12(1):7763. https:\/\/doi.org\/10.1038\/s41598-022-11835-z.","journal-title":"Sci Rep"},{"key":"7913_CR115","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18). https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","DOI":"10.1161\/CIR.0000000000001063"},{"issue":"1","key":"7913_CR116","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1373\/clinchem.2016.259564","volume":"63","author":"NE Ibrahim","year":"2017","unstructured":"Ibrahim NE, Januzzi JL. Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. Clin Chem. 2017;63(1):211\u201322. https:\/\/doi.org\/10.1373\/clinchem.2016.259564.","journal-title":"Clin Chem"},{"key":"7913_CR117","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53445","author":"M Kayani","year":"2024","unstructured":"Kayani M, Fatima N, Yarra PC, Almansouri NE, K D, Balasubramanian A, et al. Novel biomarkers in early detection of heart failure: a narrative review. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.53445.","journal-title":"Cureus"},{"issue":"2","key":"7913_CR118","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11897-017-0321-4","volume":"14","author":"V Senthong","year":"2017","unstructured":"Senthong V, Kirsop JL, Tang WHW. Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr Heart Fail Rep. 2017;14(2):106\u201316. https:\/\/doi.org\/10.1007\/s11897-017-0321-4.","journal-title":"Curr Heart Fail Rep"},{"issue":"9","key":"7913_CR119","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/bph.14603","volume":"176","author":"P Yang","year":"2019","unstructured":"Yang P, Read C, Kuc RE, Nyimanu D, Williams TL, Crosby A, et al. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol. 2019;176(9):1206\u201321. https:\/\/doi.org\/10.1111\/bph.14603.","journal-title":"Br J Pharmacol"},{"key":"7913_CR120","doi-asserted-by":"publisher","first-page":"1369489","DOI":"10.3389\/fphar.2024.1369489","volume":"15","author":"TL Williams","year":"2024","unstructured":"Williams TL, Nyimanu D, Kuc RE, Foster R, Glen RC, Maguire JJ, et al. The biased apelin receptor agonist, MM07, reverses Sugen\/hypoxia-induced pulmonary arterial hypertension as effectively as the endothelin antagonist macitentan. Front Pharmacol. 2024;15:1369489. https:\/\/doi.org\/10.3389\/fphar.2024.1369489.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7913_CR121","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12933-022-01574-w","volume":"21","author":"M Li","year":"2022","unstructured":"Li M, Yi T, Fan F, Qiu L, Wang Z, Weng H, et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):139. https:\/\/doi.org\/10.1186\/s12933-022-01574-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"7913_CR122","doi-asserted-by":"publisher","first-page":"101334","DOI":"10.1016\/j.xcrm.2023.101334","volume":"4","author":"Q Wu","year":"2023","unstructured":"Wu Q, Yao Q, Hu T, Yu J, Jiang K, Wan Y, et al. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. Cell Rep Med. 2023;4(12):101334. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101334.","journal-title":"Cell Rep Med"},{"key":"7913_CR123","doi-asserted-by":"publisher","unstructured":"Arvunescu AM, Department of Cardio-Thoracic Pathology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Department of Internal Medicine and Cardiology, Prof. Dr. Th. Burghele Clinical Hospital, Bucharest, Romania, Ionescu RF, Department of Cardiology I, Dr. Carol Davila Central Military Emergency Hospital, Bucharest, Romania, Dumitrescu SI et al. The real-world anti-inflammatory effect of SGLT2i in patients with chronic heart failure. JMedLife. 2025;18(2):155\u201364. https:\/\/doi.org\/10.25122\/jml-2025-0011.","DOI":"10.25122\/jml-2025-0011"},{"issue":"4","key":"7913_CR124","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003800","volume":"10","author":"J Butler","year":"2017","unstructured":"Butler J, Hamo CE, Udelson JE, O\u2019Connor C, Sabbah HN, Metra M, et al. Reassessing phase II heart failure clinical trials: consensus recommendations. Circ: Heart Failure. 2017;10(4):e003800. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003800.","journal-title":"Circ: Heart Failure"},{"issue":"5","key":"7913_CR125","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jacc.2021.11.033","volume":"79","author":"M Fiuzat","year":"2022","unstructured":"Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, et al. Optimal background pharmacological therapy for heart failure patients in clinical trials. J Am Coll Cardiol. 2022;79(5):504\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.033.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07913-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07913-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07913-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:27:27Z","timestamp":1784096847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07913-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":125,"alternative-id":["7913"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07913-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors did not use generative AI or AI-assisted technologies in the development of this manuscript.","order":1,"name":"Ethics","label":"Generative AI and AI-Assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}